A third fatality has been recorded among patients receiving treatment with a Sarepta gene therapy, adding to the troubles being faced by the company.

Bristol Myers Squibb (NYSE:BMY) announced on Friday that its anemia therapy, Reblozyl, developed with Merck (NYSE:MRK), did ...